FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)

View source ↗

Summary

FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) from Celgene Corporation (NDA 212327).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

SUPPL AP for INREBIC (FEDRATINIB HYDROCHLORIDE)